Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Alzheimer's disease (AD) is the most prevalent form of dementia in the elderly population worldwide.
-
46/100
A total of 13 case reports were found (10 for donepezil, 2 for galantamine and 1 for rivastigmine) with rate corrected QT interval (QTc) prolongation.
-
Alzheimer's disease (AD) is a major cause of morbidity worldwide and its prevalence is expected to rise.
-
Lithium therapy is generally accepted as a first-line treatment for bipolar disorder, and it is also identified as one of the best augmenting options for treatment-resistant depression.
-
SBME produced significant improvement on mental control, logical memory and paired associated learning during the 12-week drug therapy.
-
Alzheimer's disease, the leading cause of dementia, is defined by extracellular amyloid‑β (Aβ) plaques, intracellular tau aggregates and neurodegeneration.
-
Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4) heterozygotes or non-carriers.A group of UK neurologists, old age psychiatrists and geriatricians with expertise in AD convened to agree appropriate use recommendations for lecanemab in UK clinical practice.
-
In 2025, several major advances have marked the field of neurology.
-
Cardiovascular risk factors contribute to the majority of dementia cases, with about 20% directly attributable to vascular cognitive impairment and dementia (VCID).
-
BackgroundLecanemab and donanemab are anti-amyloid-β monoclonal antibodies recently approved in the United States and Europe for the treatment of early Alzheimer's disease (AD).
-
Alzheimer's disease (AD) is characterized by the accumulation of amyloid beta, which is strongly associated with disease progression and cognitive decline.
-
Anti-amyloid monoclonal antibodies have finally achieved their translational breakthrough after many years of unmet expectations.
-
Anti-amyloid mAbs consistently demonstrated robust amyloid clearance and modest slowing of clinical decline in early symptomatic AD.
-
The development of humanized IgG1 anti-amyloid monoclonal antibodies, such as lecanemab, provides a promising novel treatment pathway with potential disease-modifying effects for patients with early Alzheimer's disease (AD).
-
Lecanemab, a monoclonal antibody targeting β-amyloid protofibrils, has shown promising results in a Phase III clinical trial for the treatment of early stages of Alzheimer's disease (AD) and has been approved by the European Medicines Agency.
-
Alzheimer's disease (AD) is the most common type of dementia.
-
Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease.
-
Amyloid-related imaging abnormalities, were originally described by dementia care experts.
-
The Food and Drug Administration granted traditional approval of lecanemab for the treatment of Alzheimer's disease (AD).
-
Anti-amyloid immunotherapies have recently emerged as treatments for Alzheimer's disease.
-
45/100
Alzheimer's disease (AD) affects over 6 million people over the age of 65.
-
The important functions of sleep include cleaning processes such as the elimination of metabolic products, e.g., amyloid, via the glymphatic system; consolidation of memory; and anabolic regulation of metabolism.
-
We find that IRAs can cross the BBB by two separate processes; one that is fast and one that is slow.
-
GBA-related PD (GBA-PD) patients have higher risk of dementia and reduced survival than non-carriers.
-
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early Alzheimer's disease patients who have proven β-amyloid pathology (Aβ).
From across this topic
8 of the 902 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- No response to high-dose muscarinic agonist therapy in Alzheimer's disease
- The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease
- Effect of Aspirin on All-Cause Mortality in the Healthy Elderly
- Aducanumab and disease modifying treatments for Alzheimer's disease
- Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial
- The chemical biology of clinically tolerated NMDA receptor antagonists
- Drugs for Alzheimer's disease: are they effective?
- Lemborexant: First Approval